Managing costs and care with biosimilars

Biosimilars—a fast-growing class of therapeutic products that are highly similar to and have no clinically meaningful differences from existing FDA-approved branded biologics—are poised to significantly change the face of medicine in oncology, rheumatology, diabetes and many other disease categories.

For healthcare providers, the availability of biosimilars not only provides a broader array of therapeutic options, it also offers an alternative way to manage the cost of care. However, biosimilars also create new questions for providers, and many seek to better understand the clinical profile and economics of the therapies before prescribing them.

Interested in exploring biosimilars further? Cardinal Health has proven expertise and services to help.

Your source for biosimilars

As one of the largest healthcare distributors in the U.S., Cardinal Health has broad access to commercially available biosimilars, as well as a deep understanding of the clinical and economic issues related to biosimilars and their reference products.

Biosimilar drug	Biologic reference	HCPCS code	Patient support services	US launch date
Mvasi	Avastin	Q5107	Amgen Assist 360	July 2019
Zirabev	Avastin	Q5118	Pfizer Oncology Together	Dec 2019
Retacrit	Epogen/Procrit	Q5105 (ESRD use) Q5106 (non-ESRD use)	Pfizer Oncology Together	Nov 2018
Herzuma	Herceptin	Q5113	Teva Core Program	March 2020
Kanjinti	Herceptin	Q5117	Amgen Assist 360	July 2019
Ogiviri	Herceptin	Q5114	Mylan Advocate Portal	Dec 2019
Ontruzant	Herceptin	Q5112	Merck Access Program	May 2020
Trazimera	Herceptin	Q5116	Pfizer Oncology Together	Feb 2020
Fulphila	Neulasta	Q5108	Mylan Advocate Portal	July 2018
Udenyca	Neulasta	Q5111	Coherus COMPLETE Support	Jan 2019
Ziextenzo	Neulasta	Q5120	Sandoz One Source	Nov 2019
Nivestym	Neupogen	Q5110	Pfizer Oncology Together	Oct 2018
Zarxio	Neupogen	Q5101	Sandoz OneSource	Sept 2015
Avsola	Remicade	Q5121	Amgen Assist	July 2020
Inflectra	Remicade	Q5103	Pfizer enCompass	Nov 2016
Renflexis	Remicade	Q5104	Merck Access Program	July 2017
Ruxience	Rituxan	Q5119	Pfizer Oncology Together	Jan 2020
Truxima	Rituxan	Q5115	Teva Core Program	Nov 2019

Resources for learning more about biosimilars

If you are new to biosimilars, these resources may be useful:

FDA Overview on biosimilars and interchangeable products

Prescribing biosimilar products

FDA biosimilar guidance

Discover solutions for your biosimilar needs

As you consider the implications of adopting biosimilars, you may need additional insights to decipher the economic implications or consultative services to support the clinical and operational aspects of adoption. Whether you are a community-based physician practice or part of an integrated health system, Cardinal Health has proven resources to help you navigate this emerging area of therapy.

Specialty physician practices

In a specialty physician practice, you face new challenges every day to deliver high-quality care at a lower cost. We are proud to offer solutions that arm you with the insights, tools and expert support you need to make decisions related to biosimilar adoption. From biosimilar distribution services and contracted pricing to providing robust analytics around your formulary, Cardinal Health can help you chart the right course for your practice’s success.

Learn more about our tools and services for Oncology, Rheumatology, Nephrology and other specialty practices.

View our solutions

Hospitals and health systems

We are focused on providing outstanding service and easy online ordering to ensure you have the products you need, when you need them. If you have any questions about ordering biosimilars or adopting them in your facility, contact us and one of our knowledgeable sales team members will contact you soon.

Biopharma manufacturers

Whether you are looking for guidance in navigating the path to regulatory approval, help collecting real-world evidence and research to support your value story, or assistance with programs to support patients through their treatment journey, Cardinal Health has proven solutions to help you successfully commercialize your biosimilar.

See how we can help

Interested in biosimilars?

One of our knowledgeable representatives will follow up with you soon.

First name

Last name

Facility name

Permission to communicate

Yes, I would like to learn more about Cardinal Health’s products and services by email. I can withdraw my consent or change my preferences by visiting Update Preferences. Visit Privacy Policy for more information about Cardinal Health’s privacy practices.

Biosimilars: A new choice in therapy